Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model

Given the increasing prevalence of diabetes in low-income and middle-income countries (LMICs), we aimed to estimate the health and cost implications of achieving different targets for diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among LMICs. We constru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet global health 2021-11, Vol.9 (11), p.e1539-e1552
Hauptverfasser: Basu, Sanjay, Flood, David, Geldsetzer, Pascal, Theilmann, Michaela, Marcus, Maja E, Ebert, Cara, Mayige, Mary, Wong-McClure, Roy, Farzadfar, Farshad, Saeedi Moghaddam, Sahar, Agoudavi, Kokou, Norov, Bolormaa, Houehanou, Corine, Andall-Brereton, Glennis, Gurung, Mongal, Brian, Garry, Bovet, Pascal, Martins, Joao, Atun, Rifat, Bärnighausen, Till, Vollmer, Sebastian, Manne-Goehler, Jen, Davies, Justine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Given the increasing prevalence of diabetes in low-income and middle-income countries (LMICs), we aimed to estimate the health and cost implications of achieving different targets for diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among LMICs. We constructed a microsimulation model to estimate disability-adjusted life-years (DALYs) lost and health-care costs of diagnosis, treatment, and control of blood pressure, dyslipidaemia, and glycaemia among people with diabetes in LMICs. We used individual participant data—specifically from the subset of people who were defined as having any type of diabetes by WHO standards—from nationally representative, cross-sectional surveys (2006–18) spanning 15 world regions to estimate the baseline 10-year risk of atherosclerotic cardiovascular disease (defined as fatal and non-fatal myocardial infarction and stroke), heart failure (ejection fraction of
ISSN:2214-109X
2214-109X
DOI:10.1016/S2214-109X(21)00340-5